Markets
BUSINESS NEWS
- Market News
- Earnings
- Recalls
- Recession Watch
- Tech News
- Financial Crisis
- Madoff Scandal
- BloggingStocks
- Luxist
- Money Videos
INVESTING
- Stock Quotes
- Stock Charts
- Stock Ticker
- Currencies
- Portfolio
- Stock Screener
- Broker Center
- Mutual Fund Center
- ETF Center
- Money
- 24/7 Wall St.
- Financial Glossary
PERSONAL FINANCE AT WALLETPOP
- Bargains
- Banking
- Budget
- Calculators
- College Finance
- Community
- Credit
- Deals
- Debt
- Economizer
- Food
- Home
- Fraud
- Insurance
- Interest Rates
- Loans
- Mortgages
- Real Estate
- Recalls
- Recession
- Retirement
- Saving
- Simplification
- Specials
- Taxes
SMALL BUSINESS
Rigel 3Q loss narrows on lower costs
SOUTH SAN FRANCISCO, Calif. (AP) — Rigel Pharmaceuticals Inc. said Tuesday its third-quarter loss narrowed as the development-stage biotechnology company completed two midstage studies in its rheumatoid-arthritis program.
The company lost $26.7 million, or 70 cents per share, compared with a loss of $37.7 million, or $1.03 per share, a year ago. There was no reported revenue during either quarter and the company still does not have a product on the market.
Analysts polled by Thomson Reuters, on average, expected a loss of 58 cents per share on revenue $3.8 million.
Rigel said stock-based compensation fell by about half, while operating expenses fell 31 percent to $26.7 million.
The company ended the quarter with cash, cash equivalents and available for sale securities of $156.1 million.
Rigel is developing treatments for rheumatoid arthritis, asthma, allergies and cancer. Partners on various programs include Serono SA, Pfizer Inc. and Merck&Co.